197 related articles for article (PubMed ID: 35545234)
41. Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant.
Chapman FA; Dickerson JE; Daly C; Clancy M; Geddes C
Ann Transplant; 2019 Dec; 24():625-630. PubMed ID: 31806862
[TBL] [Abstract][Full Text] [Related]
42. Hyperkalemia and high-dose trimethoprim/sulfamethoxazole.
Hsu I; Wordell CJ
Ann Pharmacother; 1995 Apr; 29(4):427-9. PubMed ID: 7633023
[TBL] [Abstract][Full Text] [Related]
43. Reversal of trimethoprim-induced antikaliuresis.
Reiser IW; Chou SY; Brown MI; Porush JG
Kidney Int; 1996 Dec; 50(6):2063-9. PubMed ID: 8943491
[TBL] [Abstract][Full Text] [Related]
44. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
Ahmed A
J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
[TBL] [Abstract][Full Text] [Related]
45. K(+)-sparing diuretic actions of trimethoprim: inhibition of Na+ channels in A6 distal nephron cells.
Schlanger LE; Kleyman TR; Ling BN
Kidney Int; 1994 Apr; 45(4):1070-6. PubMed ID: 8007576
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of laboratory disturbance risk when adding low-dose cotrimoxazole for PJP prophylaxis to regimens of high-grade glioma patients taking RAAS inhibitors.
Coppens R; Yang J; Ghosh S; Gill J; Chambers C; Easaw JC
J Oncol Pharm Pract; 2019 Sep; 25(6):1366-1373. PubMed ID: 30124122
[TBL] [Abstract][Full Text] [Related]
47. Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids.
Jinno S; Akashi K; Onishi A; Nose Y; Yamashita M; Saegusa J
Rheumatol Int; 2022 Aug; 42(8):1403-1409. PubMed ID: 34263352
[TBL] [Abstract][Full Text] [Related]
48. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
[TBL] [Abstract][Full Text] [Related]
49. Effect of preparation method for radioactive iodine therapy on serum electrolytes.
Takata N; Miyagawa M; Okada T; Kawaguchi N; Fujimoto Y; Kouchi Y; Tsuruoka S; Uwatsu K; Kido T
Jpn J Radiol; 2023 Nov; 41(11):1247-1254. PubMed ID: 37184818
[TBL] [Abstract][Full Text] [Related]
50. Safety of the concomitant use of methotrexate and a prophylactic dose of trimethoprim-sulfamethoxazole.
Kwon OC; Lee JS; Kim YG; Lee CK; Yoo B; Hong S
Clin Rheumatol; 2018 Dec; 37(12):3215-3220. PubMed ID: 29383453
[TBL] [Abstract][Full Text] [Related]
51. Adverse reactions to trimethoprim/sulfamethoxazole in AIDS.
Floris-Moore MA; Amodio-Groton MI; Catalano MT
Ann Pharmacother; 2003 Dec; 37(12):1810-3. PubMed ID: 14632594
[TBL] [Abstract][Full Text] [Related]
52. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia.
Ferrazzini G; Klein J; Sulh H; Chung D; Griesbrecht E; Koren G
J Pediatr; 1990 Nov; 117(5):823-6. PubMed ID: 2231218
[TBL] [Abstract][Full Text] [Related]
53. Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.
Autmizguine J; Melloni C; Hornik CP; Dallefeld S; Harper B; Yogev R; Sullivan JE; Atz AM; Al-Uzri A; Mendley S; Poindexter B; Mitchell J; Lewandowski A; Delmore P; Cohen-Wolkowiez M; Gonzalez D;
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084742
[TBL] [Abstract][Full Text] [Related]
54. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of
Harada T; Kato R; Sueda Y; Funaki Y; Takata M; Okazaki R; Hasegawa Y; Yamasaki A
Mod Rheumatol; 2021 May; 31(3):629-635. PubMed ID: 32820678
[TBL] [Abstract][Full Text] [Related]
55. Population kinetic-pharmacodynamic analysis of serum potassium in patients receiving sulfamethoxazole/trimethoprim.
Hirai T; Shiraishi C; Nakai S; Ushiro M; Hanada K; Iwamoto T
Basic Clin Pharmacol Toxicol; 2022 Nov; 131(5):380-391. PubMed ID: 36000348
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.
Dudley MN; Levitz RE; Quintiliani R; Hickingbotham JM; Nightingale CH
Antimicrob Agents Chemother; 1984 Dec; 26(6):811-4. PubMed ID: 6335381
[TBL] [Abstract][Full Text] [Related]
57. [Case of trimethoprim-induced hyperkalemia complicating ANCA-associated vasculitis].
Shishido T; Ryuzaki M; Futatsugi K; Takimoto C; Kobayashi E; Handa M; Itoh H
Nihon Jinzo Gakkai Shi; 2012; 54(5):615-21. PubMed ID: 22991842
[TBL] [Abstract][Full Text] [Related]
58. Randomized clinical trial of rifampin-trimethoprim and sulfamethoxazole-trimethoprim in the treatment of localized urinary tract infections.
Stein GE; Gurwith D; Gurwith M
Antimicrob Agents Chemother; 1988 Jun; 32(6):802-6. PubMed ID: 3046481
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
[TBL] [Abstract][Full Text] [Related]
60. Evaluating the risk of hyperkalaemia and acute kidney injury with cotrimoxazole: a retrospective observational study.
Rajput J; Moore LSP; Mughal N; Hughes S
Clin Microbiol Infect; 2020 Dec; 26(12):1651-1657. PubMed ID: 32220637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
